fbpx

Solid Tumors Trials

Bayer 20324 ON-TRK

ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib

AbbVie M19-037

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combination of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/ or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

Seagen SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

LabCorp PREFER

Prospective registry of advanced stage cancer (PREFER) patients to assess prevalence of actionable biomarkers and driver mutations using the OmniSeq test and creation of a biobank from community cancer clinics in the United States to address disparities in precision medicine

Natera 20-43-NCP Bespoke IO

BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO).

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.